Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises FAM AB on the acquisition of Sandvik Process Systems
Mandate

Vinge advises FAM AB on the acquisition of Sandvik Process Systems

June 02, 2017 M&A

Vinge advises FAM AB on the acquisition of Sandvik Process Systems (”SPS”) from Sandvik AB at a price of approximately SEK 5 bn.

Sandvik Process Systems delivers advanced industrial process solutions based on high-end steel belts, steel belt based equipment and process solutions within adjacent technologies. The transaction is subject to competition clearance.

Vinge’s team includes responsible partner Jonas Johansson and counsel Matthias Pannier together with partners Eva Fredrikson and Assur Badur, counsel Johan Cederblad and associates Karl Klackenberg, Mathilda Persson, Johanna Wiberg, Sara Strandberg, Sofia Ekdahl, Grant McKelvey, Johan Wahlbom, Isabell Nielsen, Rebecka Weitzberg, Karin Virding, Linn Adelwald, Carolina Sandell, Jasmin Draszka-Ali, Hedvig Ekdahl, Olof Johannesson, Siri Dunér as well as VDR specialist Anna Hellohf.

Related

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

 Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025